Smolen JS, Siebert S, Korotaeva TV, et al. - Assessing 6-month effectiveness of ustekinumab vs tumor necrosis factor inhibitor (TNFi) for psoriatic arthritis (PsA), it was revealed that treatment targets were reached similarly after 6 months of use of ustekinumab and TNFi in patients with PsA.

• A prospective, observational cohort study (PsABio) involved PsA patients who received first-line to third-line ustekinumab or a TNFi.

• In the final analysis set of 868 patients, proportions of those in ustekinumab/TNFi treatment groups attaining clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) low disease activity (LDA) at 6 months were 45.7%/50.7%.

• Achievement of cDAPSA remission was evident in 14.9%/19.2%, and minimal disease activity (MDA) was achieved in 26.4%/30.8% of patients.

• For ustekinumab vs TNFi, PS-adjusted odds ratios of reaching cDAPSA LDA and MDA were 0.73 and 0.87, suggesting no significant difference.

• Predictive factors were similar to earlier published evidence, and new risk factors for unfavourable outcome were: cDAPSA and 12-item Psoriatic Arthritis Impact of Disease scores and chronic widespread pain at baseline.

• Similar safety was observed between groups.